The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Analysis of Drug Interactions
Abstract
Most of the current therapies against cancer, and also those against immune diseases or viral infections, consist of empirically designed combination strategies, combining a variety of therapeutic agents. Drug combinations are widely used because multiple drugs affect multiple targets and cell subpopulations. The primary aim is a mutual enhancement of the therapeutic effects, while other benefits may include decreased side effects and the delay or prevention of drug resistance. The large majority of combination regimens are being developed empirically and there are few experimental studies designed to explore thoroughly different drug combinations, using appropriate methods of analysis. However, the study of patterns of possible metabolic and biological interactions in preclinical models, as well as scheduling, should improve the development of most drug combinations. The definition of synergism is that the combination is more effective than each agent separately, e.g., one of the agents augments the actions of the second drug. The definition of antagonism is that the combination is less effective than the single agents, e.g. one of the agents counteracts the actions of the other. A combination can be studied by combining the two agents in various different ways, such as simultaneous or sequential combination schedules. It is essential to test the potency of a combination, before evaluation in the clinic, to prevent antagonistic actions. However, one should realize that an antagonistic action may be desired when toxicity is concerned, i.e. one drug decreases the side effects of another drug. Several attempts have been made to quantitatively measure the dose-effect relationship of each drug alone and its combinations and to determine whether a given combination would gain a synergistic effect. One of the most widely used ways to evaluate whether a combination is effective is the median-drug effect analysis method. Using this method, a combination index (CI) is calculated from drug cytotoxicity or growth inhibition curves. To calculate a CI, the computer software Calcusyn can be used, taking the entire shape of the growth inhibition curve into account for calculating whether a combination is synergistic, additive, or antagonistic. Here, we describe how combinations can be designed in vitro and how to analyze them using Calcusyn or Compusyn. Moreover, pitfalls, limitations, and advantages of using these combinations and Calcusyn/Compusyn are described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity
Gordon Steel, G., & Peckham, M. J. (1979) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(79)90044-0 · Cited by 908
Keepers, Y. P., Pizao, P. E., Peters, G. J., van Ark-Otte, J., Winograd, B., & Pinedo, H. M. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90142-z · Cited by 460
Self-citationANTAGONISTS OF NUCLEIC ACID DERIVATIVES
Elion, G. B., Singer, S., & Hitchings, G. H. (1954) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)65573-5 · Cited by 427
Basis for effective combination cancer chemotherapy with antimetabolites
Peters, G. J., van der Wilt, C. L., van Moorsel, C. J. A., Kroep, J. R., Bergman, A. M., & Ackland, S. P. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00086-3 · Cited by 301
Self-citationGiovannetti, E., Lemos, C., Tekle, C., Smid, K., Nannizzi, S., Rodriguez, J. A., Ricciardi, S., Danesi, R., Giaccone, G., & Peters, G. J. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.042382 · Cited by 158
Self-citationKanzawa, F., & Saijo, N. (1997) · PubMed · Cited by 58
Cited by
Gao, Q., Feng, J., Liu, W., Wen, C., Wu, Y., Liao, Q., Zou, L., Sui, X., Xie, T., Zhang, J., et al. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114445 · Cited by 267
Wan, X., Beaudoin, J. J., Vinod, N., Min, Y., Makita, N., Bludau, H., Jordan, R., Wang, A., Sokolsky, M., & Kabanov, A. V. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.032 · Cited by 201
Statistical determination of synergy based on Bliss definition of drugs independence
Demidenko, E., & Miller, T. W. (2019) · PLOS ONE · doi:10.1371/journal.pone.0224137 · Cited by 187
Sen, K., Banerjee, S., & Mandal, M. (2019) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2019.04.035 · Cited by 110
Lara, H. H., Guisbiers, G., Mendoza, J., Mimun, L. C., Vincent, B., Lopez-Ribot, J. L., & Nash, K. L. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s151285 · Cited by 104
Metadata
- Authors
- Bijnsdorp, I. V., Giovannetti, E., & Peters, G. J.
- Venue
- Methods in Molecular Biology
- Publisher
- Humana Press
- Published
- 2011
- Volume
- 731
- Pages
- 421-434
- ISSN
- 1064-3745 (ISSN-L)
- 1940-6029
- OpenAlex
- W196543165
- Cited by
- 252
- References
- 12
- FWCI
- 19.30
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Analysis of Drug Interactions. https://app.cochat.ai/papers/10.1007/978-1-61779-080-5_34
- The paper
- Bijnsdorp, I. V., Giovannetti, E., & Peters, G. J. (2011). Analysis of Drug Interactions. Methods in Molecular Biology. https://doi.org/10.1007/978-1-61779-080-5_34
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.